Kalaris Therapeutics Market Risk Adjusted Performance
| KLRS Stock | | | 8.67 -0.50 -5.45% |
This technical indicator view for Market Risk Adjusted Performance organizes signals for Kalaris Therapeutics and comparable instruments. Availability can vary by instrument;
Equity Screeners offers additional screening access. Kalaris Therapeutics has a market cap of 171.5 M. See
Correlation Analysis for portfolio-level analysis. This suggests a position in Kalaris Therapeutics within the allocation view. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in real.
Our
How to Buy Kalaris Stock guide explains the steps to invest in Kalaris Therapeutics stock.
Kalaris Therapeutics has current Market Risk Adjusted Performance of
-22.11.
MRAP | = | ER[a] + (1/BETA - 1) | X | ER[a] - RFR) |
| = | -22.11 | |
| ER[a] | = | Expected return on investing in Kalaris Therapeutics |
| RFR | = | Risk Free Rate of return. Typically T-Bill Rate |
| BETA | = | Beta of the asset with market or selected benchmark. |
Kalaris Therapeutics Market Risk Adjusted Performance Peers Comparison
Kalaris Market Risk Adjusted Performance Relative To Other Indicators
Kalaris Therapeutics is rated
below average in market risk adjusted performance relative to competitors. It is currently under evaluation in maximum drawdown relative to competitors .
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.